. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Arch Phys Med Rehabil. 2011 Dec;92(12):2000–2005. doi: 10.1016/j.apmr.2011.07.194

Table 1.

Demographics of study participants

	Nondemented (n=50)		Alzheimer's disease (n=31)
Age	73.1 (6.7)		74.2 (5.7)
Gender (% female)	54%		48%
	Baseline Visit	Follow-up Visit	Baseline Visit	Follow-up Visit
CDR Sum of Boxes	0 (0.1)	0 (0.1)	2.8 (1.1)	4.5 (3.7)
Mini-Mental Status Exam^*	29.5 (0.8)	29.2 (1.3)	26.6 (2.5)	23.1 (7.8)
Β-blocker use (n)	1	1	3	4
Acetycholinesterase Inhibitor use (n)	0	0	15	26

p<0.001 between groups at baseline and follow-up. Values for age, CDR Sum of Boxes and Mini-mental Status Exam represent means (standard deviation). Pharmaceutical use expressed in number of individuals taking drug at time of exercise test.